Atreca (NASDAQ:BCEL) Receives “Buy” Rating from Cowen

Cowen reissued their buy rating on shares of Atreca (NASDAQ:BCEL) in a report issued on Wednesday, AnalystRatings.com reports.

A number of other equities analysts have also issued reports on the company. Stifel Nicolaus started coverage on Atreca in a research note on Monday, July 15th. They set a buy rating and a $28.00 price target for the company. Canaccord Genuity started coverage on Atreca in a research note on Monday, July 15th. They set a buy rating and a $23.00 price target for the company. Finally, Evercore ISI started coverage on Atreca in a research note on Monday, July 15th. They set an outperform rating and a $16.63 price target for the company.

Shares of NASDAQ BCEL opened at $16.65 on Wednesday. The firm’s fifty day moving average price is $14.70. Atreca has a 1 year low of $10.29 and a 1 year high of $20.00.

Atreca (NASDAQ:BCEL) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($3.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($2.90). On average, equities research analysts predict that Atreca will post -3.08 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley bought a new stake in shares of Atreca during the 2nd quarter worth $43,000. Cubist Systematic Strategies LLC bought a new stake in shares of Atreca during the 2nd quarter worth $106,000. Point72 Hong Kong Ltd bought a new stake in shares of Atreca during the 2nd quarter worth $144,000. Pentwater Capital Management LP bought a new stake in shares of Atreca during the 2nd quarter worth $471,000. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of Atreca during the 2nd quarter worth $499,000. 0.05% of the stock is owned by institutional investors and hedge funds.

Atreca Company Profile

Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Featured Story: What is a trade deficit?

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.